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A comprehensive translational cancer research approach focused on per-
sonalized and precision medicine, and covering the entire cancer research–
care–prevention continuum has the potential to achieve in 2030 a 10-year
cancer-specific survival for 75% of patients diagnosed in European Union
(EU) member states with a well-developed healthcare system. Concerted
actions across this continuum that spans from basic and preclinical
research through clinical and prevention research to outcomes research,
along with the establishment of interconnected high-quality infrastructures
for translational research, clinical and prevention trials and outcomes
research, will ensure that science-driven and social innovations benefit
patients and individuals at risk across the EU. European infrastructures
involving comprehensive cancer centres (CCCs) and CCC-like entities will
provide researchers with access to the required critical mass of patients,
biological materials and technological resources and can bridge research
with healthcare systems. Here, we prioritize research areas to ensure a bal-
anced research portfolio and provide recommendations for achieving key
targets. Meeting these targets will require harmonization of EU and
national priorities and policies, improved research coordination at the
national, regional and EU level and increasingly efficient and flexible fund-
ing mechanisms. Long-term support by the EU and commitment of Mem-
ber States to specialized schemes are also needed for the establishment and
sustainability of trans-border infrastructures and networks. In addition to
effectively engaging policymakers, all relevant stakeholders within the
entire continuum should consensually inform policy through evidence-
based advice.
1. Introduction
Recently, the European Academy of Cancer Sciences
(EACS) and several European organizations and can-
cer centres joined forces to define common goals for
the implementation of a mission-oriented approach to
cancer in Horizon Europe, initially proposed by Celis
and Pavalski in 2017 [1–3]. The aim is ‘to have an
impact on society at large by uniting countries to sub-
stantially reduce the enormous cancer burden in the
European Union (EU) and improve the health-related
quality of life of patients by promoting cost-effective,
evidence-based best practices in cancer prevention,
treatment, and care’. As highlighted previously, the
main goal is to ‘achieve a 10-year cancer-specific sur-
vival for ¾ of the adult patients diagnosed in year
2030 in Member States with a well-developed health-
care system. Because cancer mortality provides a time-
lier assessment of progress also capturing advances in
both therapeutics and prevention, it will be important
to document the expected declining trends of age-stan-
dardized mortality in each EU country’ [1,2]. The
objectives of the mission must be mindful of the needs
of the European patients and citizens at large, by
bringing maximum value for public investment, and to
ensure that health technologies developed by funding
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through the mission are available to those who need
them for a fair and affordable price.
This goal can only be achieved by integrating and
bridging the entire continuum of cancer research, pre-
vention and care, which spans from basic, epidemio-
logical and preclinical research to clinical, prevention,
implementation and survivorship research. Particular
attention should be paid to the gap between research
and cancer care, and research and prevention. Differ-
ent disciplines are involved in this endeavour each with
their own specific emphasis. These include the follow-
ing: (a) cancer biology (basic and preclinical research);
(b) identification of healthy individuals at risk of
developing cancer (primary prevention); (c) early can-
cer detection (secondary prevention); (d) cancer patient
treatment and research (clinical); and (e) support for
cancer survivors (tertiary prevention). Assessing pro-
gress in these areas requires different methodological
approaches [4–6]. Outcomes research for both thera-
peutic interventions and the effectiveness of public
health interventions and health services will be critical
for progress assessment. This will require adequate
resources, multidisciplinary expertise, access to large,
high-quality data sets including patient records, suit-
able analysis tools and coordinated collaborative pro-
jects. Taken together, all the above elements are
essential for achieving science-driven medical and
social innovations and their resulting intervention tra-
jectories, all tailored to the individual needs of patients
[2].
The latter goal emphasizes the need to create inte-
grated, networked and geographically distributed
infrastructures that can entail Comprehensive Cancer
Centres of Excellence (CCCoEs) meeting the Excel-
lence standards of the EACS [7], Comprehensive Can-
cer Centres accredited by the Organisation of
European Cancer Institutes (OECI), cancer research
and clinical centres and technological platforms. CCCs
are crucial to establish closer links between research
and healthcare systems [8,9]. By integrating cancer care
and prevention with research and education, CCCoEs
and CCCs are well-positioned to boost innovation and
deliver state-of-the-art comprehensive multidisciplinary
cancer care. Only a few designated CCCs do incorpo-
rate paediatric care as paediatric cancer patients often
also require specific expertise only available in children
hospitals. Nevertheless, further concentrating paedi-
atric oncology in centres with the necessary critical
mass can boost innovation and effectiveness of the
treatment of children with cancer. Across Europe, the
integration of cancer research and clinical care for chil-
dren and adolescents needs to address the exquisite cir-
cumstances of this patient population, as has been
demonstrated in the successful launch of the European
Commission (EC) supported Paediatric Cancer Expert
Reference Network (https://paedcan.ern-net.eu/). Geri-
atric patients, which constitute a much larger group,
are best served by CCCs that have specific pro-
grammes focussed on the specific needs of elderly
patients.
In this update, which accommodates the input of many
European cancer organizations, we provide a more
detailed view of the infrastructural requirements to pro-
mote excellence in cancer research. We also emphasize
consensus priority areas to realize the cancer mission
objectives and outline recommendations for engaging
professionals and institutions throughout Europe.
2. Infrastructures to support cancer
research of excellence
We want to emphasize that creativity, originality,
curiosity and a visionary foresight among individual
scholars or teams of investigators remain the engine
for innovation and discovery. However, these investi-
gators need to be embedded in infrastructures of suffi-
cient critical mass. This is essential for effectively
linking basic, translational, clinical and prevention
cancer research with care, as well as for driving inno-
vation across the whole cancer research/care/preven-
tion continuum. Such infrastructures would provide
researchers access to essential technology platforms,
resources and patients.
Multidisciplinary/professional patient-centred insti-
tutions are best positioned to (a) support basic and
translational research, (b) link research with the
healthcare systems including prevention organizations,
(c) offer pharmaceutical and biotechnology industries
strategic partnerships, (d) generate intellectual property
and engage in profitable technology transfer, (e) pro-
vide training, capacity building and mobility of
researchers and clinicians across Europe, (f) facilitate
the communication and dissemination of information
and finally (g) provide the best care for patients
(Fig. 1A). Networks of such institutions, accessible to
research teams across Europe, will be essential to
achieve the goals. Specialized academic medical/cancer
research centres are critical especially for primary pre-
vention research and intervention research [10]; their
particular target population of healthy individuals and
their research often based on observational rather than
intervention studies, with links to basic research, epi-
demiology, public health and social and human
sciences.
We propose three networked research infrastructures
accessible to research teams from across Europe that
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will be essential to achieve the goals. The three infras-
tructures should focus on translational research, clini-
cal and prevention trials, and outcomes research
(Fig. 1B).
2.1. Infrastructure for translational research
Translational research bridges basic/preclinical
research with clinical and prevention research, builds
on inventions and innovation from basic/preclinical
research, and has a direct impact on therapeutic and
prevention research [1,3]. This should result in proof
of principle clinical/prevention trials that, if successful,
subsequently require research for effective implementa-
tion in the healthcare system.
A comprehensive infrastructure for translational
research linked to clinical research will require:
 A robust basic cancer research programme.
 Close interactions between innovative basic/pre-
clinical research, molecular and digital pathol-
ogy, a variety of omics technologies and
immunotyping facilities for patient stratification.
 A bidirectional translational research structure.
 Data acquisition tools and structured databases
with possibilities for computational analyses rele-
vant for both therapeutics and prevention stud-
ies.
 Reduced fragmentation of oncology data sources
through a well-functioning European Health
A B
Prevention
research
network
Outcomes
research
network
Fig. 1. Research networks provide cancer researchers with sufficient critical mass of research infrastructures, patients, samples, technology
and expertise. (A) Paradigm of a translational research network. Multidisciplinary, patient-centred institutions, such as CCCs and CCCoEs,
each having a broad research scope, interact closely. For example, they collaborate on specific research items (indicatively, on breast cancer
(BC), or lung cancer (LC)) and share platform technologies, thereby forming the core components of a translational research infrastructure.
CCCs and CCCoEs are best positioned to: (i) support basic and translational research through crosstalk with cancer centres (CCs) and
cancer research institutes (CRIs), as well as linking to academic research at universities, for example, research on (bio)chemistry,
engineering, genetics, molecular and cell biology, tumour biology, immunology; (ii) exchange data to improve care for patients both at top
clinical hospitals and community hospitals; (iii) work closely with start-ups and offer pharmaceutical and biotechnology industries strategic
partnerships; (iv) provide training, capacity building and mobility of researchers and clinicians across Europe through twinning programmes;
(v) generate intellectual property and engage in profitable technology transfer, facilitating the communication and dissemination of
information. (B) Infrastructures involve interacting networks. These networks too are based on the close collaboration among researchers in
CCCs, CCCoEs, clinical CCs, universities and other research organizations (see also panel A). The three suggested types of infrastructures
(translational research, clinical and prevention trials, and outcomes research) may in addition include structures addressing specific research
requirements. An already-established paediatric oncology network exemplifies how innovative research and clinical strategies can be
delivered, based on strong collaboration across European centres. In the context of a cancer mission, all networks would establish cross-
border relationships with each other, and also with existing independent research clusters and professional clusters focusing, for example,
on health economics, computational sciences, psychosocial oncology or palliative care. In addition, strong links to national screening
facilities, and EU-wide patient records, databases and biobanks can be established and maintained.
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Data Space with focus on the integration of real-
world data sources and harnessed quality-of-life
data; data safety, open science and FAIR princi-
ples (findable, accessible, interoperable and reu-
sable). Harmonized interoperability standards,
data sharing.
 Innovative imaging technologies, with a focus on
novel molecular and functional imaging.
 Facilities and expertise to develop and imple-
ment cell-based and other biological therapies.
 High-quality pharmacology.
 Biobanks with associated patient records.
 Capacity for ‘proof-of-concept’ clinical/preven-
tion trials.
 Longitudinal sampling routines (tumour biop-
sies/consecutive biopsies and liquid biopsies).
 Interaction with clinical-trials consortia or net-
works to develop practice-changing clinical tri-
als.
2.2. Infrastructure for clinical and prevention
trials
‘Proof-of-principle’ studies may serve as a starting
point for further clinical and prevention research,
including the assessment of its utility in health care or
prevention, and patient-reported outcomes. Well-devel-
oped clinical trial structures, as well as advanced diag-
nostic methods, such as state-of-the-art molecular
pathology, omics technologies and pharmacology to
stratify patients, are crucial.
Due to a large number of tumour subgroups, the
traditional clinical trials methodology built on the
phase I–IV trial concept are gradually being super-
seded by new more sophisticated stratification methods
[11–14]. Moreover, there are increasing possibilities to
follow therapy response using innovative imaging tech-
nologies, consecutive tumour biopsies and/or liquid
biopsies [15]. Such biopsies permit treatment adjust-
ment to the changing biology of the tumour. However,
it will be essential to monitor closely whether these
more advanced and potentially costly interventions
improve patient outcome; implementation research can
determine this.
Implementation research needs to include health
economics of therapeutic interventions and prevention
programmes for early detection on large patient popu-
lations, to inform on their clinical utility, benefits and
harms to patients and the healthcare system at large.
In addition, patients’ experiences during new treatment
approaches have to be considered. The patient’s gen-
der and age are also parameters that need to be
carefully weighed in clinical trial designs. Paediatric
oncology is an obvious example, but this equally holds
for elderly patients. Given the ageing population, age
may be considered as an essential parameter in the
implementation (adaptation of therapeutic strategies,
importance of supportive care, presence of comorbidi-
ties and frailties) and evaluation (health-related quality
of life) of clinical and prevention trials.
By contrast, as primary prevention mostly addresses
harmful exposures and behaviours, research is observa-
tional and often requires hundred thousands of indi-
viduals in multinational study series to draw firm
conclusions. Implementation of protective measures
and secondary prevention effectiveness and efficacy
can be evaluated in field trials, with the individual or
sometimes even communities, serving as observational
units [5]. Tertiary prevention, although involving the
cancer patient, usually follows the individual well
beyond the time they are in contact with a cancer hos-
pital.
A comprehensive infrastructure for clinical and pre-
vention trials will require:
 Availability of sufficiently large numbers of
diverse patient groups for clinical research to
develop personalized/precision cancer medicine,
in case of prevention trials access to large num-
bers of healthy subjects.
 Molecular pathology including multi-omics tech-
nologies and immunotyping for stratification of
patients and healthy subjects for distinct treat-
ment arms.
 State-of-the-art infrastructure for early clinical
trials, next-generation clinical trials, practice-
changing clinical trials and implementation
research.
 Follow-up monitoring/treatment adaptation by
repeated biopsies and functional/molecular imag-
ing technologies.
Comprehensive cancer centres and CCCoEs (Fig. 2)
often fulfil many of these requirements as far as the
clinical trial trajectory is concerned. They are further
complemented with clinical research networks, many
in collaboration with Organisation for the Research
and Treatment of Cancer (EORTC), an organization
that will play a significant role in this infrastructure.
However, CCCs currently lag behind in implementa-
tion research, which we consider an essential aspect
that needs to be addressed. Prevention research is not
sufficiently covered in most CCCs and also requires
distinct infrastructures which might vary depending on
the nature of the trial. Clearly, it has to include strong
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epidemiology, biostatistics, data acquisition capacity
and advanced computational capabilities. IARC fulfils
a critical international role in this latter domain, and
Cancer Prevention Europe (CPE) is expected to make
critical EU-focused contributions.
2.3. Infrastructure for outcomes research
Evidence of the effectiveness of therapeutics and pre-
vention strategies is essential for the assessment of
clinical utility, cost-effectiveness and prioritization [16].
In addition to showing effectiveness in clinical and
prevention trials, evidence of effectiveness in day-to-
day clinical practice is required. For therapeutics, data
from quality-assured clinical registries are indispens-
able for evaluating effectiveness. Outcomes research in
therapeutics addresses questions related to all aspects
of the clinical pathway, including treatment optimiza-
tion, side effects of treatments, long-term follow-up
with assessment of health-related quality of life, reha-
bilitation and survivorship, as well as attention to
social aspects. This should preferably be a collabora-
tive effort between clinicians, researchers and epidemi-
ologists. For prevention, outcomes can be measured
using data from population-based registries for cancer
incidence and mortality.
Areas of research that need special attention for
patients living with cancer are rehabilitation, psycho-
oncology, sequelae prevention and supportive care for
palliative oncology, as well as survivorship [17]. Since
around half of all cancer patients in the EU will ulti-
mately need palliative care (nearly all patients that die
Fig. 2. Overview of Accredited CCCs and Cancer Centres in Europe.
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from cancer), this area requires specific attention. Out-
comes research has to differentiate between: (a) sup-
portive care when cure is no longer possible but life
extension with a good health-related quality of life still
is a reasonable goal and (b) palliation at the end of
life. Patients with rare cancers and in specific vulnera-
ble age ranges, that is, children and the elderly will
need more tailored regimes.
A network of CCCs with consistently structured
clinical registries will be instrumental for collecting the
necessary data and formulating research questions. By
stimulating collaborations between CCCs, the critical
mass will be in place for effective outcomes research.
The EACS plans together with OECI to identify the
criteria for designation of CCCoEs and CCCs, which
will be instrumental for Outcomes Research.
A comprehensive infrastructure for outcomes
research will require:
 Extensive collaboration among clinicians, epi-
demiologists and other researchers in CCCoEs,
CCCs, clinical cancer centres, universities and
other research organizations. Use of networks
within networks, an infrastructural model
designed by Cancer Core Europe, will be essen-
tial for high-quality outcomes research.
 Competencies in epidemiologic theory, biostatis-
tics, bioinformatics, artificial intelligence (AI)—
including big data and machine learning—as well
as communication technology, which should
become an integrated part in many aspects of
cancer research, treatment and prevention.
 Well-structured databases with preclinical, clinical
and socio-economic data, and data from observa-
tional studies (patient registries/databases). These
databases, preferentially deposited in EU-con-
trolled data centres, should allow linkage to ran-
domized data platforms. Eligible patients can be
invited to participate. State-of-the-art computa-
tional tools need to be linked to the databases.
 Pan-European databases on patients with rare
cancers. Outcomes research on rare cancers is
difficult to achieve in individual countries due to
the limited number of cases. The European Ref-
erence Networks can play here an important role
(https://ec.europa.eu/health/ern/networks_en).
 Complete and updated national cancer registries.
The NORDCAN database provides an example
of easily accessible data on cancer incidence and
death (https://www-ep.iarc.fr/NORDCAN/Eng
lish/frame.asp).
 Comprehensive and updated national cause of
death registries.
 Transparent data-sharing policies. This is a criti-
cal prerequisite to perform effective outcomes
research.
2.4. Infrastructure models
The models of the infrastructures suggested above can
be based on the structures of some existing networks
and some key recommendations listed below. CCCs
such as those accredited by the OECI [9], the German
Cancer Aid [18], or CCCoEs designated by the EACS
with focus on translational research [7] will be key
components of the three infrastructures. These centres
are well-positioned to form networks, both nationally
and internationally, and some indeed have done so,
both within and beyond national boundaries. Net-
works composed of CCCoEs, CCCs, cancer research
institutes and clinical centres with well-developed inte-
grated basic, preclinical and clinical research, as well
as relevant technical platforms, will be important ele-
ments of the infrastructures (Fig. 1B). Institutional
collaborations will enable the recruitment of suffi-
ciently large patient cohorts, access to biological mate-
rials and technological resources, as well as the
establishment of sustainable large-scale research pro-
grammes. Cancer Core Europe is an example of a
translational cancer research consortium for therapeu-
tics [19–21], and CPE an example of a network for
prevention research [5,22]. These consortia share com-
mon interests, and their close interaction will be cru-
cial to explore the biology underlying known and new
causes of cancer. Such interactions can result in new
prevention programmes and diagnostic technologies to
detect malignant disease at an early stage, thereby per-
mitting treatment that is more effective.
The network model of infrastructures adopted by
Cancer Core Europe is based on institutional collabo-
rations (legal entity) among seven large cancer centres
across Europe, most of which are CCCs [19–21]. The
German Cancer Research Consortium (DKTK) is a
national entity linking eight CCCs; moreover, within
the frame of the German National Decade against
Cancer, a German consortium of six National Centres
for Tumour diseases is under development to structure
the clinical part of the research continuum as well as a
National Cancer Prevention-Development Strategy.
Another prime example of a national network is the
Cancer Research UK network of 15 translational
research centres, which are funded to the tune of
€230 million a year (https://www.cancerresearchuk.
org/funding-for-researchers/our-research-infrastructure/
our-centres) on top of competitive grant funding. A
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further example of a national legal entity linking 20
Cancer Centres in France is Unicancer (http://www.uni
cancer.fr/en/patients/unicancer-charter) furthering
translational and clinical research, and clinical
improvements. An additional example is the collabora-
tive initiative taken by paediatric oncologists through
the European Society of Paediatric Oncology (SIOPE;
https://siope.eu/encca/).
2.5. Recommendations for creating the three
types of infrastructures for innovative cancer
research
2.5.1. Create networks of CCCs and CCCoEs
Today around 35 CCCs are accredited in Europe, 22 by
the OECI and 13 by the German Cancer Aid; two
CCCoEs are already certified by the EACS (Fig. 2). It is
essential to have at least one CCC in each country acting
as a nucleus from which expertise and best practices are
disseminated within the country, and some larger Mem-
ber States might need 10 or more CCCs. Newly accred-
ited CCCs, generated through supportive partnership
arrangements, should result in networks of CCCs/
CCCoEs and other centres (both within Member States
and across borders) to innovate and perform high-quality
multidisciplinary cancer research and provide high-qual-
ity cancer care, including health-related quality of life
and survivorship research. They may also conduct pre-
vention research and offer prevention services depending
on how health care is organized in each country.
CCCoEs, on the other hand, should provide advanced
infrastructural facilities. To increase the number of
CCCs, institutions that have capabilities to become a
CCC or an accredited clinical centre need to be incen-
tivized by establishing funding opportunities to reach the
standards required for formal accreditation by the OECI
[23]. Countries that do not have CCCs are recommended
to establish at least one CCC, through appropriate fund-
ing instruments (e.g. cohesion funds).
2.5.2. Generate incentives for ‘twinning’ a CCC or
clinical centre with an established CCCoE or equivalent
high-quality centre, to facilitate the training of
specialists and researchers
The aim is to increase the knowledge and skills of can-
cer professionals and to promote research collabora-
tions, thereby boosting healthcare innovation (Fig. 1).
‘Twinning’ could be initiated from clinical centres (or
individuals working in these locations) that aspire to
accreditation, or from established CCCs that want to
reach out to raise the standards of centres elsewhere.
The funding mechanism should be flexible and avoid
unnecessary bureaucracy. Examples are already in
place: The German Cancer Research Centre (DKFZ,
Heidelberg) has twinned with the Athens CCC (http://
www.accc.gr/), and the Swedish Karolinska Institute
(KI, Stockholm) is in discussion about expanding an
existing formalized collaboration with the National
Institute of Oncology NIO, Budapest, into a twinning
partnership (https://onkol.hu/kutato-osztalyok/?la
ng=en and https://onkol.hu/department_of_selenopro
tein_research/?lang=en). Experiences acquired through
these collaborations could help the development of
new ‘twinnings’. Cancer Core Europe is supporting
this development, and the engagement of the recently
established Central-Eastern European Academy of
Oncology (CEEAO) could play a strategic role in this
endeavour (https://hungarytoday.hu/kasler-central-ea
stern-european-academy-of-oncolog/). The OECI, the
EACS and the European Association of Cancer
Research (EACR) will be of critical importance in the
areas of training and education.
To make an impact, however, the infrastructures
need to be sustainable. Only then, a number of such
collaborative entities can be created and the inclusion
of institutions in all EU Member States secured. The
ERA-NET TRANSCAN (https://www.era-learn.eu/net
work-information/networks/transcan-2), for example,
offers a strategy to support international translational
cancer research collaborations and will greatly benefit
from the proposed infrastructures. Developing and
expanding infrastructures will require open access to
knowledge, transparent access rules to data, commit-
ment from all Member States, alignment of European
and national funding sources, as well as instalment of
strong governance and management.
3. Research portfolio: areas of priority
The cancer mission aims to apply and expand present
knowledge to reduce cancer incidence and mortality
and to improve health-related quality of life by pro-
moting affordable, evidence-based best practices in
cancer prevention, treatment and care. Coordinated
multidisciplinary research in the consensus areas high-
lighted below, supported by the networked infrastruc-
tures described above, will be necessary to achieve the
mission goals.
3.1. Basic and preclinical research
Basic research is essential to enlighten our understand-
ing of the molecular mechanism underlying cancer [24]
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and is the engine that fuels innovation in both preven-
tion and therapeutics [1,25]. Our recommendations
(Box 1) may help maximize the potential of basic and
preclinical research which provide the basis for speed-
ing up the translation of discoveries into clinical and
potentially preventive applications that impact
patients’ lives and benefit society at large.
A number of research areas are expected to have a
bearing on the innovation of prevention and therapeu-
tics research. Research towards identification of new
causes of cancer through unravelling mechanisms of
carcinogenicity, the biology underlying premalignant
and malignant lesions, identification and validation of
biomarkers for detecting premalignant disease, and
elucidation of the role of ageing and comorbidities in
the emergence and progression of malignant clones is
expected to result in new preventions strategies. In
addition, for development of therapeutics with a focus
on medical oncology, the following are vital: predic-
tion of antitumour effects and side effects of treat-
ment; development of technologies to stratify patients
for treatment; innovation of precision pharmacological
monitoring; mechanisms underlying drug and
immunotherapy resistance, and how to overcome
them; as well as characterization and manipulation of
the tumour microenvironment. Innovation in imaging
and radiation therapy is dependent on basic/preclinical
research [26]. Involvement of computational sciences
will gain more in-depth insight into cancer biology and
clinical/prevention cancer research.
3.2. Primary prevention
Primary prevention research has provided recommen-
dations to decrease, for example, tobacco smoking,
alcohol consumption and exposure to UV radiation by
the sun or UV devices and to maintain a normal body
weight [27]. Figure 3 puts the preventable fraction of
cancers through primary prevention in the context of
the increasing European cancer burden. However,
implementation is often inadequate [5]. For some pre-
ventive measures known to be successful, there are
political and societal barriers delaying or even hamper-
ing implementation; notably, cigarette smoking
remains responsible for almost half of all preventable
cancer cases in Europe [22]. For many other known
harmful exposures or unhealthy behaviours, the most
effective and efficient preventive strategies are not yet
identified. Consequently, implementation research is
essential to augment the effectiveness of such pro-
grammes. Such research should address awareness in
society, particularly concerning attitudes and lifestyles,
as well as the role of authorities in regulating the con-
sumption of harmful substances and exposure to envi-
ronmental carcinogens. Additional research areas, such
as public health, sociology, and behavioural science,
have to be integrated into this research. If behavioural
change is the goal of the preventive measures, it is
essential to include expertise in these areas (Box 2).
Box 2
Recommendations for primary prevention.
 Support implementation research to enhance the
effectiveness and efficacy of prevention programmes
that address well-known risk factors (tobacco, UV
exposure, alcohol consumption, overweight) and if
effective would substantially reduce cancer incidence
throughout the EU.
 Support continued aetiological research to uncover
new causes of cancer, genetic predisposition and the
influence of behavioural and environmental factors.
 Support population health intervention research to
develop operational strategies and policies in cancer
prevention, for example new primary prevention
strategies (vaccination, medical) that are less expen-
sive and easy to implement, independent from the
expenditure on health
 Promote research to elucidate the individual and soci-
etal cognitive processes behind successful behavioural
preventative interventions and to address the socio-
economic and commercial determinants of health.care
in a particular country.
 Promote behavioural/nudging, area-based/territory-
based/community-based intervention research linked
to prevention, by engaging scientists from disciplines
less represented in cancer research today, such as
behavioural, communication and social sciences.
 Overall funding for prevention research must increase
substantially, and new areas of research must be
included.
Box 1
Recommendations for basic and preclinical research.
 Encourage multidisciplinary projects (cancer biology,
chemistry, immunology, radiobiology, engineering,
computational science, public health).
 Promote high risk–high return projects.
 Promote research in poor prognosis cancers.
 Engage researchers from all EU countries.
 Use ERC funding paradigms to select the most
promising bottom-up proposals.
 Facilitate participation of small and medium enter-
prises and industry.
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Prevention research should involve identification of
causes of cancer and individuals at high risk (exposure
and genetic predisposition) using epidemiological
research coupled with mechanistic studies, including
interactions of risk factors. Research is needed to
reduce carcinogenic exposures (environment, work-
place) and addiction to carcinogenic substances as well
as to uncover underlying biological and social mecha-
nisms. Behavioural research linked to changing lifestyle
patterns that increase cancer risk and long-term side
effects of treatment and offering active primary preven-
tion (e.g. vaccination, novel targets for medical preven-
tion) is other relevant research areas. Implementation
research should be structured and optimized (Box 2).
3.3. Early detection for prevention and treatment
The distinction between early benign disease and pre-
malignant disease likely progressing to invasive/meta-
static disease is still difficult [28]. Identification of early
markers, obtained from early lesions or liquid biopsies,
that predict progression to malignant disease, will be
extremely valuable for effectively eliminating malig-
nant disease early. In addition, combining early detec-
tion with the identification of individuals at high risk,
based on lifestyle and/or genetic predisposition, will
enhance the innovation and effectiveness of screening
and early detection programmes [29]. Programmes of
early detection will be critical particularly within pri-
mary- and community care, linked to the expertise and
data in specialist centres within networks. The impact
of the COVID-19 crisis has already shown large falls
in symptomatic presentations to primary care, and
screening [30]; (https://www.bbc.com/news/health-
52985446). This fragility points to the need for tar-
geted presymptomatic interventions offered to individ-
uals based on risk profile.
Fig. 3. Newly diagnosed patients with cancer estimated for the year 2018 and projected for the year 2040 for Europe (UN definition), the
predicted new cancer burden for the total period from 2018 to 2040, and the preventable cancer burden in 2018 had primary prevention
against the listed established causes of cancer been rigorously implemented [22] (Source: J. Sch€uz—Modifiable risk factors and prevention:
overview of current knowledge and main challenges; European Code against Cancer initiative. Health Working Group; Environment, Public
Health and Food Safety (ENVI) Committee of the European Parliament, 18/2/2020: https://www.europarl.europa.eu/cmsdata/196417/
Schuz_modifiable%20risk%20factors.pdf).
Box 3
Recommendations for early detection.
 Critically evaluate currently applied early detection
methods and their target populations, and select and
promote/disseminate those with proven benefit for
broader implementation in the EU.
 Promote biological characterization of premalignant
disease that progress to invasive and metastatic can-
cer.
 Stimulate biomarker discovery and development of
diagnostic technologies for early detection of lesions
that are likely to progress to cancer.
 Support the development of innovative low-cost
devices, methods, and programmes that permit effec-
tive early detection with high specificity.
 Develop the concept of prevention screening based on
relevant early detection.
 Provide support for their industrial production, test-
ing and validation for use in daily practice.
 Encourage implementation research of early detection
programmes, assess participation and analyse factors
that affect compliance.
 Analyse clinical effectiveness and health economics of
early detection programmes.
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Significant research initiatives are already devoted to
identify the specific characteristics of early lesions and
to develop new diagnostic methods [31]. However, much
remains to be learned, and it will require substantial
efforts to develop valid predictive diagnostic assays for
early detection of malignant disease. Once promising
methods are available, well-structured implementation
research will be needed to evaluate their effectiveness in
screening programmes. Assessment of clinical effective-
ness combined with health economics is critical. The
outcome of early detection and treatment has to be com-
pared to the outcome of treatment following manifesta-
tion of clinical symptoms. This type of information will
be necessary to prioritize early detection programmes
within the EU and to assure that the most effective
screening programmes are rolled out first. In addition,
swift access to medical care is essential for individuals
experiencing symptoms that warrant further examina-
tion. More research on the impact of healthcare systems
on early detection is needed. We also need effective
approaches to make the population more aware of early
signs of disease. Our recommendations for early detec-
tion are summarized in Box 3.
3.4. Development of new therapies
The number and proportion of academia-initiated clini-
cal trials (including diagnostics, medical and clinical
oncology, radiation therapy, translational associated
research, surgery and multimodal treatment) should
increase with the specific aim of improving survival and
health-related quality of life, with particular emphasis
on precision medicine and age/gender-specific aspects.
New functional and molecular imaging technologies
should be evaluated for effectiveness in clinical trials.
Methodologies for predicting treatment outcomes,
both positive and negative, are essential for personal-
ized/precision cancer medicine and already receive
ample attention in medical oncology, with focus on anti-
cancer agents and immunological treatments [32,33].
Targeting multiple tumour driving pathways by combi-
nations of targeted drugs applied concurrently or in a
specific order may increase the efficacy of treatment by
circumventing mechanisms of primary or acquired resis-
tance [34]. Expanding molecular pathology by multi-
omics technologies to identify tumour drivers and con-
ducting high-throughput functional in vitro screens in
cells carrying the same lesions might lead to new combi-
nation therapies and offer opportunities for drug repur-
posing [35].
Immunological interventions with checkpoint inhibi-
tors, antibodies, vaccination programmes and cell ther-
apies show ample promise [36–40]. In addition,
developments in radiobiology and radiophysics have
boosted innovation in radiation therapies; for example,
novel fractionated radiation regimens, use of different
sources (photons, protons and light ions), or combina-
tion with other treatments offer new perspectives [41–
45]. Surgical treatment is moving towards technologies
with improved preservation of organ function and
integration with both radiation therapy and medical
anticancer treatment [41,46]. Predicting the best possi-
ble intervention will increasingly be guided by big data
analyses requiring the contribution of machine-learn-
ing algorithms and computational sciences [47].
Early clinical research delivers proof-of-concept out-
comes that might have practice-changing potential.
However, it requires further studies to assess their
potential value for the health care. For wide imple-
mentation in the healthcare system, clear criteria need
to be defined for outcomes. Clinical effectiveness has
to be assessed in regular practice by collecting real-life
data through implementation research. Survival bene-
fits linked to information on side effects and health-re-
lated quality of life should illustrate the added value
compared to current standard treatment. Outcomes of
the implementation research should serve as the new
gatekeeper when randomized comparative clinical tri-
als cannot be used. Our recommendations for develop-
ment of new therapies are summarized in Box 4.
3.5. Psychosocial oncology, rehabilitation, and
survivorship research
Psychosocial oncology, rehabilitation, and survivorship
are closely related areas. As the recommendations for
each of these areas show substantial overlap, we
describe the relevant issues of each first and then pro-
vide an overarching set of recommendations (Box 5).
3.5.1. Psychosocial oncology research
Psychosocial interventions have shown improvement in
emotional and social functioning and health-related
quality of life in a large meta-analysis [48]. Psychoso-
cial oncology is an essential component within the
entire clinical trajectory. Technologies to identify
patients at risk for psychological distress and to select
the most appropriate intervention strategy need further
development. Psychosocial oncology can also play a
vital role in addressing lifestyle problems as part of
prevention programmes, including tertiary prevention
as a part of rehabilitation. Psychosocial interventions
encompass many research areas such as behavioural
science (psychology), epidemiology, public health
science, nursing research, sociology and biostatistics.
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Communication with patients and relatives is critical,
given the new diagnostic and treatment modalities
aimed at personalized/precision cancer medicine [49].
Information for the patients will increase in complexity,
making it essential to develop tools to ensure that
patients fully understand the options available for
informed choices in the context of shared decision-mak-
ing. Communication with patients is also complicated
by the often-conflicting information patients collect
from the internet. With the diversification of treatments
and growing number of cancer patients with chronic dis-
ease, the demand for information will continue to grow.
Developing guidelines and standards for psychosocial
care should be an integral part of implementation
research for evaluating programme effectiveness; which
patients are offered the interventions and how do they
perceive the intervention. A range of demographic, cul-
tural/ethnic, social, clinical and intervention-related
characteristics can influence the relative effectiveness of
psychosocial interventions. Thus, it is important to fur-
ther develop and test tailored psychosocial interventions
that fit the needs of specific subgroups of patients as well
as individual patients [48,50]. Research is also needed to
identify the psychosocial needs of patients and their
families along the entire continuum from diagnosis
through treatment and into the survivorship phase.
Although there are a number of well-researched,
psychometrically sound and widely used measures for
monitoring the symptom burden, psychosocial needs
and quality of life of patients with cancer, additional
work is needed [51,52]. This work could take advan-
tage of available and emerging technologies, such as
the use of mobile devices to detect problems at rele-
vant points in time, and eHealth interventions that
make psychosocial interventions more accessible to a
larger number of patients at lower costs. A promising
development is the use of modern test theory, and par-
ticularly item-response theory models and computer-
adaptive testing to refine the assessment of patient-re-
ported outcomes at the individual patient level.
Despite a large number of publications, further trials
are needed to evaluate the health-related quality of life
assessment protocols. Methodological development
should focus on new study designs that take advantage
of the Internet and wireless acquisition of physical and
psychological data. The complexity of assessing health-
related quality of life is increasing with the clinical tri-
als methodology weighting more towards personalized/
precision cancer medicine [53,54]. The latter is a moti-
vation to conduct more research to develop relevant
questionnaires.
3.5.2. Rehabilitation research
Rehabilitation is of vital importance for the outcome
after cancer treatment [17]. Rehabilitation should focus
Box 4
Recommendations for development of new therapies.
 Increase support to academia-initiated clinical trials (including diagnostics, drug development, radiation therapy, asso-
ciated translational research, surgery and multimodal treatment).
 Encourage and support research in drug repurposing to find new applications of well-established and widely available
generic medicines.
 Adopt existing and create new innovative investigator-initiated trial concepts such as Drug Rediscovery Protocol or
basket studies, exploring new engagement paradigms with the pharmaceutical industry.
 Support treatment optimization research to identify the optimal dosage and duration of existing treatments, both for
the benefit of patients and to guarantee the sustainability of healthcare systems.
 Improve stratification methods of patients using multi-omics, novel complex multilayer biomarkers based on systems
biology models.
 Develop methodologies for predicting treatment outcomes (in silico studies).
 Stimulate development and application of new functional and molecular imaging technologies (including radiomics).
 Increase support to already-established multicentre platforms for early drug development.
 Develop new sophisticated in vitro and in vivo functional screening methods (e.g. Interspaced clustered regularly short
palindromic repeats/Cas9 based in preclinical models, i.e. Patient-derived xenografts or organoids) to identify new
therapeutic paradigms.
 Support the development of academic cell therapy entities (e.g. Chimeric antigen receptor T cells cell production) to
boost further innovation in less toxic immunotherapy approaches.
 Promote integration of advanced computational methods (AI, machine learning) with clinical research.
 Structure implementation research in therapeutics to effectively introduce practice-changing therapies.
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on three areas: physical, mental health affected by psy-
chological consequences of diagnosis and treatment
and, finally, social health (e.g. as influenced by profes-
sional reintegration, altered family relationships and
financial constraints). High age, comorbidities and
frailty [55] are important risk factors for the develop-
ment of side effects; examples of adverse long-term
effects of disease and intervention are treatment-in-
duced cardiotoxicity, neurotoxicity, impaired fertility
and sexual problems, cognitive impairment and fati-
gue. Identification and prediction of side effects and
psychological complications can assist in the choice of
therapy and therefore represent essential research
areas. The latter also holds for identification of the
needs for supportive care and psycho-oncological assis-
tance. Research is needed to identify the most effective
and efficient intervention strategies for returning to
work [10].
For timely detection of complications, long-term fol-
low-up is necessary. Patient-reported outcomes could
prove very useful in this regard. Outcomes research
should be used for reversed translation to research and
design innovative rehabilitation strategies.
3.5.3. Survivorship research
The goal to achieve 10-year cancer survival for 75% of
patients by 2030 poses a major medical, socio-eco-
nomic, legal, as well as a political challenge. We need
to articulate the most relevant stigmas associated with
cancer and convey the message that cancer is no
longer a death sentence with cancer survivors having
the right to return to a normal life upon recovery.
Cancer survivorship is strongly influenced by the
side effects of treatment with a significant impact on
patients, the healthcare system and society overall.
Long-term adverse effects have consequences for
patients’ physical, mental and social health. A review
by the former EACS Taskforce on Cancer Survivor-
ship was recently published [56] where survivorship
was defined as the phase after active cancer treatment.
Survivorship research—the last component of the can-
cer research continuum and an integrated part of the
translational research—has a bearing on the evaluation
of multiple outcomes, including symptom burden,
functional health, health-related quality of life and
socio-economics. Information collected from surviving
Box 5
Recommendations for psychosocial oncology, rehabilitation, and survivorship research.
 Support methodological development for assessment of health-related quality of life.
 Develop tools to enhance communication with patients and shared decision-making (e.g. increasing patients’ access to
their medical records via patient portals, development and testing of decision aids for selecting from available treat-
ments).
 Establish international collaboration for developing survivorship-specific patient-reported outcomes in order to moni-
tor the physical and psychosocial health and health-related quality of life of individuals in the post-treatment period.
This is a prerequisite for establishing effective programmes to address the individual needs of cancer survivors (e.g.
return to work, fertility, sexuality, reconstruction surgery, dental health, cognitive functioning, fear of recurrence, etc.).
 Develop, test and implement apps and wearable devices for effective follow-up monitoring and appropriate interven-
tions.
 Support research to create a comprehensive overview of the negative consequences of a cancer diagnosis and treatment
on physical, mental and social health in the short and the long term.
 Develop prediction models for side effects of treatments.
 Support long-term follow-up programmes notably for paediatric and young cancer patients to conduct large-scale, lon-
gitudinal, observational studies in distinct cohorts of cancer survivors to better understand their problems and needs.
 Establish and assess outcomes of guidelines to facilitate return to social health, enable reintegration in the workforce
and alleviate financial and legal constraints (e.g. life insurance, mortgage).
 Identify health and social inequalities in the cancer survivorship population.
 Initiate research on the economic consequences cancer survivors and their relatives are facing. This should include
both direct and indirect costs.
 Evaluate the need for and effectiveness of survivorship care models used in various healthcare systems.
 Conduct research to better understand the causes of differences and discrimination in the survivorship experience
between countries and cultures, including financial services such as loans and mortgages.
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cancer patients may help identify and reduce long-term
side effects of treatment and improve rehabilitation
and psychosocial services.
Closer cooperation between clinicians and patients
in multidisciplinary and interdisciplinary survivorship
research is needed at a Pan-European level to identify
socio-economic inequalities, including disparities
among the EU Member States and in particular the
Central and Eastern European (CEE) countries. Rein-
tegration in the workplace and social life, as well as
equal rights to take out loans and mortgages, is essen-
tial study areas. New legal rules that protect cancer
survivors against economic discrimination need to be
articulated and proposed to the legal authorities.
The increasing cancer survivorship has initiated dis-
cussions about the necessity of specialized cancer sur-
vivorship clinical structures within or outside the
CCCs, to address the need for infrastructures/facilities
for long-term follow-up and support of cancer sur-
vivors [17]. Long-term follow-up is particularly rele-
vant for paediatric and young cancer patients. The
development of patient-reported outcomes surveys tai-
lored to the cancer survivor population is required to
ensure that chronic physical and psychosocial health
needs can be addressed in an effective and timely man-
ner [57].
3.6. Palliative oncology
Supportive care is multidisciplinary and must accom-
modate the patient’s needs. With cancer increasingly
becoming a chronic disease following continuous or
intermittent treatments, supportive palliative care is
crucial until end-of-life palliation. Improved therapies
translate in life prolongation, but also cause side
effects that need recognition, as the overall goal is life
prolongation while maintaining a good health-related
quality of life.
Emerging evidence suggests that early integration of
palliative and oncological care improves symptom con-
trol, health-related quality of life and even entails a
significant life prolongation [58–60] and higher satis-
faction among caregivers [61]. Currently, there is a
need to establish supportive care teams or home care
teams with expertise not only in caring for the dying
patient, but also to address problems, symptoms and
side effects associated with palliation among patients
surviving for months or years [62]. Our recommenda-
tions for palliative oncology are detailed in Box 6.
Development and validation of health-related qual-
ity of life assessment methodologies—including psy-
chosocial or existential aspects relevant to patients
with severe complications of late-stage cancer—are
urgently needed. Advances in preclinical research
might also help to mitigate symptoms, especially in
patients with pain or cancer cachexia.
3.7. Paediatric oncology
Across Europe, there are more than 35 000 new paedi-
atric cancer cases annually and > 6000 children and
adolescents dying from cancer each year. Two-thirds
of the almost half a million childhood cancer survivors
in Europe live with the long-term effects of treatment,
which can be severe, affecting their daily lives and
socio-economic participation [63]. While there are
interactions across the age spectrum, childhood can-
cers have a unique set of challenges compared to adult
cancers, including the specific types of cancers, the
underpinning biology, the clinical pathways, the long-
term physical and psychosocial impact and, crucially,
the long-term support of a sick child by their family.
Childhood cancer accounts for 20% of childhood
deaths after infancy and is the leading cause of child
mortality from disease in Europe [64]. The European
paediatric oncology community already has an exten-
sive track record in the successful delivery of innova-
tive research and clinical strategies from strong
collaborative research networks that have markedly
improved outcomes. The improvements in the diagno-
sis and treatment of childhood cancers over the past
four decades were built on a strong foundation of
cross-border, multidisciplinary, international research,
more recently supported by EU Framework funding
programmes.
These established, integrated research and clinical
networks are well-positioned to deliver a further ambi-
tious and integrated programme of international
research. The launch of the European Reference
Box 6
Recommendations for palliative oncology.
 Increase research efforts to evaluate the optimal orga-
nization of supportive care because emerging cancer
treatments often permit a substantial life prolonga-
tion.
 Integrate supportive care teams or home care teams
into oncological care; implementation should depend
on proven clinical effectiveness.
 Promote development and assessment of educational
programmes teaching palliative care professionals
how to recognize and mitigate potentially life-threat-
ening side effects resulting from specific treatments
(targeted drugs, immunotherapy).
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Network for Paediatric Oncology (ERN PaedCan) in
March 2017 heralded the start of a framework for
national healthcare systems to cooperate in the care of
children with cancer. International cooperation is
essential in the complex and rare disease setting that
characterizes childhood cancers. The ERN PaedCan
infrastructure enables access to state-of-the-art diag-
nostics and treatment and facilitates cross-border
exchange of disease-specific expertise. Further building
on this infrastructure will reduce the current inequali-
ties in childhood cancer health care, while also provid-
ing a scaffold to integrate research networks (Box 7).
In 2015, SIOPE, in partnership with the patient
advocate groups Childhood Cancer International-Eur-
ope and Unite2Cure, published a detailed long-term
strategic plan focused on health care and research ini-
tiatives to increase survival and the quality of life for
children and adolescents with cancer in Europe by
2025 [65]. This strategic plan is evolving to keep pace
with emerging innovations and should become part of
a European mission to beat cancer. Focus on innova-
tive therapies including precision medicine, next to fur-
ther research in the biology of paediatric tumours, is
an important goal. In addition, equal access to the
standard of care and specific attention to teenagers
and young adults is an important goal as well as more
attention for survivorship issues.
3.8. Geriatric oncology
Cancer is a group of diseases mainly affecting individ-
uals at an advanced age, with diagnosis usually above
60 years and death above 70 years. Ageing and cancer
are both associated with the accumulation of muta-
tions in DNA [66], and, among other changes, ageing
affects the hematopoietic clonal heterogeneity (desig-
nated either as ARCH for age-related clonal haemato-
poiesis or as CHIP for clonal haematopoiesis of
indeterminate significance).
Clones defined by mutations in proto-oncogenes and
tumour suppressor genes accumulate in most tissues
with ageing, including skin [67], oesophagus [68,69],
liver [70], colon [71], lung [72] and many others [73].
In the oesophagus, for example, a strong positive
selection of clones carrying mutations in distinct can-
cer genes was identified. With ageing, these clones
cover much of the epithelium, with NOTCH1 muta-
tions affecting up to 80% of cells. Surprisingly, their
prevalence is higher in normal tissue than in oesopha-
geal cancers [68].
Widespread positive selection of mutant clones may
contribute to tissue ageing by negatively affecting tis-
sue function. Toxic exposures will further increase the
mutational burden, as observed in the bronchial
epithelium of tobacco smokers [72] and hepatocytes of
cirrhotic patients [70]. Furthermore, cells might also
become senescent [74]. And although no longer cap-
able to divide, these cells can create an inflammatory
environment promoting tumour progression [74].
Currently, many research questions are linked to
mutation load and ageing, as well as senescent cells
that accumulate during ageing and are associated with
a distinct secretory phenotype. These age-related
changes undoubtedly also influence cancer therapy.
Therefore, more information is needed regarding the
relationship between ageing and cancer (Box 8). We
also need to understand how ageing affects treatment
feasibility and efficacy and to what extent cancer and
cancer treatment accelerate ageing. Targeting senescent
Box 8
Recommendations for geriatric oncology.
 Support basic research aiming at understanding the
links between ageing and cancer.
 Support clinical research in elderly to optimize treat-
ment.
 Develop instruments, for example frailty scales rele-
vant for oncologic patients, and methods of data col-
lection for assessment of health-related quality of life
in geriatric cancer patients, with an eye for their
often-extensive comorbidities.
Box 7
Recommendations for paediatric oncology
 Support of paediatric cancer projects by investment in
research and innovation to specifically combat child-
hood cancer and reduce disparities.
 Invest in an integrated programme of research to real-
ize the seven key objectives of the SIOPE strategic
plan:
i Innovative therapies
ii Precision medicine in health care
iii Increase biology knowledge of paediatric tumours
iv Increase equal access to standard care, expertise
and clinical research
v Address the needs of teenagers and young adults
vi Improve the quality of survivorship
vii Understanding the causes of paediatric cancers
and addressing prevention where possible.
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cells may become a therapeutic strategy to either pre-
vent or treat cancer as well as to mitigate other
chronic diseases (Box 8).
High age and comorbidities are regularly exclusion
criteria in clinical trials. As a result, we often lack evi-
dence on treatment benefits among older patients.
There is a need for clinical trials that analyse dose
escalation and de-escalation, combinations therapies,
the impact of comorbidities and the influence on
health-related quality of life (Box 8).
3.9. Outcomes research
Outcomes research is essential for assessing the degree
to which the goals and objectives of a cancer mission
are achieved (Box 9). We need to select robust meth-
ods to follow the expected reduction in mortality and
increase in long-term survival. We also need methods
to compare outcomes of EU countries and monitor
whether inequalities indeed decrease. Outcomes
research linked to health economics is fundamental for
priority setting with an important role for patients/pa-
tient organizations. Lead-time bias due to early detec-
tion and overdiagnosis of nonlethal cancer has to be
taken into consideration when survival benefits are
analysed. Interpretation of trends in cancer patient
survival is indeed challenging and never straightfor-
ward [75]. There is a need to define time frames for
short-term (5 years) and long-term goals. Increases in
the 10-year survival rate among patients diagnosed
through 2030 will be impossible to assess until 2040.
Outcomes research has been a missing element in
large parts of translational studies (see the chapter on
infrastructures). CCCs should contribute with quality-
Box 9
Recommendations for outcomes research.
Different domains of cancer need definition of distinct outcome parameters. No outcome will be relevant to all. The main
domains are cancer therapeutics and prevention.
1) Cancer therapeutics
a) Short-term
 Assess clinical effectiveness of innovations—in combination with health economics analyses as a ‘gate keeper’ before
implementation into the healthcare system.
 Monitor the percentage of patients in clinical trials and compare outcomes for patients in and outside clinical trials.
 Study short-term overall survival to mitigate effects of lead-time bias and possible overdiagnosis.
b) Long-term
 Study 5- and 10-year overall patient survival to mitigate effects of lead-time bias and possible overdiagnosis.
 Study 5- and 10-year cancer overall mortality and cancer-specific mortality (rate of death of cancers in the population,
stratified by age and gender, and other relevant risk factors).
 Assess all-cause mortality (although new treatments may not reduce all-cause mortality, all-cause mortality should be
used as an endpoint to ensure that harms of the new treatment do not affect other causes of death).
 Determine health-related quality of life after 5, 10 years and longer.
2) Prevention
a) Short-term
 Assess population receptivity to prevention interventions.
 Assess the potential impact of intervention programmes on the prevalence of behavioural risk factors for cancer, such
as smoking, alcohol consumption, obesity (of the whole population) as a function of intervention programmes.
 Monitor the percentages of patients and individuals included in behavioural research and in prevention trials or other
studies aiming at reducing the cancer burden.
b) Long-term
 Assess trends in cancer incidence, cancer mortality and overall mortality.
 Study effects of cancer prevention strategies on mortality in the population.
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assured and consistently structured clinical registries to
monitor assessment of clinical effectiveness of imple-
mentation, including documentation of reproducibility
of research outcomes in clinical practice. Outcomes
research is also needed to demonstrate the effectiveness
of prevention initiatives. The OECI has started pro-
grammes for the development of outcomes research,
and health services research, within its constituent
CCCs. In addition, the German Cancer Research Con-
sortium has an expanding clinical database bringing
together the information of eight of the leading Ger-
man CCCs.
Implementation of personalized/precision cancer
medicine requires scientific evidence on an increasing
number of subgroups based on new molecular pathol-
ogy/genomics diagnostic technologies. Even for com-
mon tumours, the large number of subgroups will
offer challenges similar to those in studies of rare can-
cers; for future studies to be informative, international
collaboration will often be a prerequisite, so that
patient numbers are sufficiently large for reaching sta-
tistically robust conclusions.
Outcomes research should be classified into short-
term and long-term assessment for cancer care, includ-
ing therapeutics (Box 9). Benefits of prevention, on the
other hand, can be meaningful to assess only as a
long-term effect, although short-term outcomes may
guide quality assurance and acceptability in the popu-
lation. Valid outcomes research requires high-quality
data (see above) and the ultimate outcomes are cancer
incidence, mortality and overall survival of cancer
patients.
Many population screening programmes to detect and
prevent cancer early may result in healthy individuals
undergoing unnecessary tests and treatments [76]. Early
detection screening, such as prostate and breast cancer
screening, increases the recorded incidence of cancer
[77,78]. Prevention screening such as cervical and colorec-
tal cancer screening increases the incidence of precursors
(cervical intraepithelial neoplasia for cervix and colorec-
tal polyps for colorectal cancer) but decreases the inci-
dence of invasive cancer. Efforts should be made to
improve the prognostic value of cancer screenings and
reduce the burden for the individual: to do more good
than harm—‘less tests less treatments’.
3.10. Health economics
New possibilities for cancer prevention, diagnosis and
therapies usually come from findings resulting from
public and private investments in medical research
[16]. Their numbers rise rapidly, making informed
choices necessary. This leads to an increased interest in
clinical and cost-effectiveness research. The impact on
population health depends on what one pays for in the
different European healthcare systems. Current data
reveal significant differences in inputs and outputs,
and this is reflected in the performance measures [79].
Health economics studies the unavoidable choices
between different alternatives when resources are lim-
ited. European healthcare systems differ with respect
to available resources for cancer care and how those
resources are used, but they share the same objectives
of improving outcomes for cancer patients. Develop-
ment and sharing information for making the best use
of available options given limited resources for cancer
care are a common interest.
The objective of a mission-oriented approach to can-
cer research in Europe is to improve health outcomes
for cancer patients through the development and intro-
duction of new methods for prevention, early diagnosis
and treatment of the disease, using surgery, radiother-
apy and cancer medicines. Health economics includes
the study of the efficiency and equity of resource allo-
cation to and within cancer care. A key point in the
translational research process is when decisions are to
be made about pricing and reimbursement for the
introduction of a new method or drug in clinical prac-
tice in different countries. Decision-makers, including
public payers, clinicians and patients, should have
accurate information about clinical effectiveness, costs
and overall value of the new method/drug to decide
about use and payment. These decisions are not only
important for improving outcomes for patients and
healthcare efficiency, but also for the research commu-
nity in prioritizing investments in the development of
new methods.
Often robust data on clinical effectiveness and value
for patients of new methods compared to existing
alternatives are lacking. For example, the number of
new cancer medicines increases fast. But there is rather
limited information from clinical trials on outcome
parameters, as compared to alternative treatments [80].
Follow-up studies in clinical practice have serious
shortcoming in terms of data on patient characteristics
and methodology and thus not fulfilling their potential
to contribute to evidence generation and improvements
over time [81]. The latter is a problem that cannot be
mitigated by more sophisticated health technology
assessment methods. The potential consequence is the
introduction and regular use of methods and medicines
that have little or no value, or a delay in the introduc-
tion of new treatment regimens that do improve out-
comes for patients.
At present, we have also incomplete information
about cost-effectiveness of resources used to treat
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cancer [82]. Data are lacking about the resources spent
for different types of cancer care and for different
groups of patients and how this affects outcome.
Therefore, decision-makers, including public payers,
clinicians and patients, need better information about
the potential clinical effectiveness and value of the new
method in order to make decisions about their use and
reimbursement. Health economics needs to be included
as an integral component of the translational research
pathway. Therefore, research including aspects of SES
(socio-economic status) is important in order to pro-
mote equal access to cancer care. Without public reim-
bursement through taxes or public health insurance,
appropriate cancer care is not affordable for the gen-
eral public. The pricing and budget impact of cancer
medicines on the healthcare system poses a particular
challenge and requires close monitoring of objective
benefits and costs and patients should be involved in
health economics research at all levels. Our recommen-
dations for health economics implementation are sum-
marized in Box 10.
3.11. Big data and computational science
EU-wide population databases will be indispensable
for answering some of the questions listed above,
including comparative research between geographically
distinct regions in Europe. This requires consistency in
institutional clinical registries that need to be based on
standardized patient records with genomic/molecular
marker information, providing opportunities for speci-
fic studies such as Outcomes Research and Health
Economics Research as outlined above. Assessment is
needed of the value, validity and reliability of volun-
tary patient-reported data uploaded to a single EU
digital centre and its compatibility with privacy and
‘droit d’oublier’ requirements. There is also much
work to be done on how to aggregate detailed datasets
for research purposes, while guaranteeing patient
anonymity. Work is also needed to develop AI para-
digms for mining data to identify new correlations and
meaningful algorithms (improvements in predicting
response, relapse and side effects). Sophisticated diag-
nostic methods and algorithms to interpret them are
needed to select the most promising cancer therapy for
individual patients (e.g. to avoid the commonly
observed selection of resistant clones [83–85]. Our rec-
ommendations on big data and computational science
are summarized in Box 11.
Box 10
Recommendations for health economics.
 Make the collection of data for an assessment of
cost-effectiveness a mandatory part of all clinical
research projects aimed at developing new preventive
or therapeutic methods within the cancer mission.
 Evaluate already existing methods (in fact deferred
maintenance) as a validated reference.
 All applications for clinical research grants should
include a statement of how the project will contribute
to the objectives of the mission, and a plan for how
the impact should be assessed.
 Support the development of a database carrying the
relevant information to appraise cost-effectiveness of
preventive and therapeutic innovations.
 Support the advancement of methods that assess the
social value of cancer care beyond aggregate gains in
length and quality of life of patients, that are relevant
for decisions about allocation of resources for cancer;
severity of disease condition; necessity of intervention;
prevalence of the condition; and impact on caregivers
and dependents of patients.
 Install a task force that continuously evaluates and
reports on the cost-effectiveness of new innovations in
prevention and therapeutics, as information to health-
care systems to decide on adoption and reimbursement.
The task force should also assess if the cancer mission
research programme achieves its objectives.
Box 11
Recommendations for big data and computational science.
 Stimulate introduction of AI/machine-learning
approaches in multiple areas: image analysis, whole-
genome sequencing, patient-reported outcome infor-
mation, clinical record datasets, lifestyle parameters,
prevention measures and early detection.
 Define the core data records that should be collected
from every patient, complemented with predefined
disease-specific and patient-specific records, on the
assumption that certain data stay in the treating insti-
tution unless that patient gives permission for wider
use.
 Explore whether patient-initiated data sharing pro-
vides an option to create large well-accessible and
reliable datasets without violating existing privacy
rules.
 Offer practical training courses focussed on acquiring
new computational skills relevant for research and
clinical care.
 European data protection policies need to prevent the
misuse of data without restricting the use of data.
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4. Patient empowerment
The primary focus of patient empowerment is on
improving the healthcare systems, so that the patient is
at the centre of shared decision-making.
The cancer mission aims at covering the entire
research continuum. By definition, translational cancer
research has a focus on patients and individuals at risk
and strives to improve all aspects associated with the
consequences of a cancer diagnosis. In traditional
research, patient participation was largely limited to
being the subject of research. Currently, there is a sig-
nificant cultural shift that increasingly ensures that
real-life experiences of patients are considered when
determining priorities in research areas [86].
Patients that actively participate in research focused
on unmet needs develop increased self-confidence, and
a more robust advocacy voice, making them feel more
empowered, valued and respected. Early patient
involvement in research offers opportunities for identi-
fying and influencing research questions and defining
meaningful study endpoints. Patient empowerment, as
far as cancer research is concerned, is mostly related
to unmet needs of patients.
Comprehensive cancer centres integrate care, preven-
tion, research and education enabling innovation in
multidisciplinary care. Patient perspectives are impor-
tant, and since assigning priorities to projects is
unavoidable, patients should be represented in CCC
boards, while CCC leadership also establishes formal
interactions with patient organizations.
The integration of patient advocacy in the full spec-
trum of childhood cancer research and multidisci-
plinary care is exemplified by the partnership between
ERN PaedCan and the CCI-Europe, the primary
patient and survivorship organization in Europe. CCI-
E representatives are core members of the Network’s
Oversight Committee, as well being intrinsic to the
implementation of the ERN’s objectives at the
national level.
It will be necessary to involve patients’ representa-
tives in the governing bodies of all consortia and
infrastructures mentioned earlier in this article. Simi-
larly, patients and patient organizations should have a
role in the different project areas suggested above
(Box 12).
5. Specialist education
Education must cover all components of the cancer
research/care/prevention continuum and be accessible
to researchers and cancer specialists from all EU coun-
tries to reach the goals of the mission on cancer [87].
Leading European cancer organizations [EACR,
EACS, European CanCer Organisation, ECPC, Euro-
pean Molecular Biology Organization (EMBO),
EORTC, European Society for Medical Oncology
(ESMO), European Society of Surgical Oncology,
Box 12
Recommendations for patient empowerment.
 Support primary and secondary prevention with a focus on individuals with modifiable risk.
 Involve patients and patient organizations in prioritizing therapeutic research areas.
 Support rehabilitation research, and research focussing on health-related quality of life issues (supportive care, psy-
chosocial oncology, palliative care and survivorship) including patients and families for shared decision-making.
 Involve patients and patient advocacy organizations in prioritizing research areas in outcomes research and health eco-
nomics. This should also include assessment of the socio-economic impact on patients and their families (/households/
relatives/dependents and caregivers), and the identification of patient groups particularly vulnerable to impairments of
their socio-economic situation due to cancer and cancer care.
 In areas where research focuses on how to decrease present inequalities, patients and patient organizations should be
enabled to play a pro-active role.
 Shared decision-making should ensure that all medical and social consequences of a cancer diagnosis are considered.
 Education is a prerequisite to reach the goals of the mission. Both European Cancer Patient Coalition (ECPC), Asso-
ciation of European Cancer Leagues and SIOPE have extended educational programmes for patients, relatives and the
public. Increase collaborations with CCCs and consortia of research centres will be necessary to further expand the
educational activities.
 Communication and diffusion of information are vital to bring science and technology to society and to emphasize
their importance for generating science-driven and social changes that impact the lives of patients. The mission govern-
ing body, cancer patient organizations, national cancer societies, universities and hospitals, policymakers as well as the
press, should broadly disseminate the information.
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European Society Radiotherapy and Oncology, Feder-
ation of European Biochemical Societies and SIOPE]
regularly organize conferences and support educational
courses. In addition, Cancer Core Europe organizes an
annual Summer School for Translational Cancer
Research, the OECI focus on the comprehensiveness
of cancer care and the ECPC on education centred on
patients and their relatives. Trainings in cancer preven-
tion are currently organized irregularly and would ben-
efit from a more systematic approach, both reaching
out to medical and public health professionals.
An inventory of educational activities within the
EurocanPlatform project revealed an impressive
amount of educational activities in 23 participating
cancer research centres (https://cordis.europa.eu/projec
t/id/260791/reporting). Making courses accessible to
students and professionals from all Member States will
increase knowledge and promote networking.
Exchange of researchers will foster new research col-
laborations in consortia of cancer centres. Further-
more, the twinning of centres can greatly help in
disseminating expertise and establishing a critical
research culture. Implementing our recommendations
as outlined above and summarized in Box 13 will
decrease inequalities across EU countries and facili-
tates capacity building. Specific educational pro-
grammes targeting the next generation of leaders will
support sustainability and increase interaction between
research centres as exemplified by Cancer Core Eur-
ope.
6. Inequalities in research
Emphasizing the link between cancer outcomes and
research activities, the EC recognized that increasing
the quality and quantity of research capacities is
needed to improve outcomes for cancer patients with
specific attention to high-risk individuals in the Mem-
ber States (https://ec.europa.eu/programmes/horizon
2020/sites/horizon2020/files/SPH_VisionPaper_0206201
6.pdf) [88].
To reduce disparities with the primary aim to
improve patient survival as well as the health con-
sciousness in the Central and Eastern EU region, Prof
Miklos Kasler, Minister of Human Capacities, Hun-
gary, took the lead in bringing 21 countries together.
His initiative resulted in the foundation of the CEEAO,
within which institutions join forces in fighting cancer
in a population encompassing 260 million people. In
January 2020, the governing council and the scientific
advisory board of CEEAO were elected at its general
assembly in the Hungarian Parliament. The organiza-
tion aims at harmonizing cancer control plans in the
region with a focus on cancer care, prevention and edu-
cation. As an example of a well-functioning consortium
within the region under the umbrella of CEEAO, the
wide-ranging, coherent activities of Central-Eastern
European countries within the Central-Eastern Euro-
pean Breast Cancer Surgical Consortium are worth
mentioning. The ERN PaedCan has already achieved
at least one ‘node’ per country in Central/Eastern Eur-
ope for development of paediatric oncology.
Despite the presence of excellent basic and clinical
research in some areas, translational research activities
largely suffer from insufficient funding and limited col-
laborative activities in the Central and Eastern EU
region [89]. For example, a dedicated cancer research
fund is not available in many countries. In addition,
the number of clinical trials (in particular early clinical
trials and investigator-initiated trials) is lagging in this
region [90]. Hence, innovation in prevention, early
detection and treatment could have a significant
impact on cancer incidence and survival in many Cen-
tral and Eastern European countries. To this end, tigh-
ter collaboration between clinical and basic research
activities should be enabled primarily by strengthening
the scientific activities of accredited cancer centres.
Our recommendations for addressing inequalities in
cancer research are summarized in Box 14. As noted
above, the OECI’s and EACS’s accreditation and des-
ignation programmes should serve as primary quality
control of translational cancer research and its integra-
tion into high-quality patient care in Europe. CCCs
accredited for their care, research and education
should play a central role in fulfilling the aims of the
cancer mission. In parallel, the accreditation pro-
gramme intrinsic to the ERN PaedCan is driving qual-
ity for research for cancer in children and young
individuals. These entities constitute the powerhouses
not only of high-quality cancer research in Europe;
they also provide the best opportunity and model for
a strong interaction between research and multidisci-
plinary health care, a pivotal element to ensure that
innovations benefit patients.
Box 13
Recommendations for specialist education.
 Establish recurrent educational and scientific confer-
ences prepared by the organizations mentioned above.
 Organize theoretical training courses.
 Create a new European comprehensive culture of edu-
cation, training and lifelong learning.
 Extend the reach of educational courses by arranging
participation also through the internet.
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Out of the 40 OECI accredited centres, 22 hold the
CCC designation and 18 are designated as clinical
‘Cancer Centres’ (CC), which represent recognized,
high-quality clinical centres, although with significantly
less research output. Inequalities become immediately
evident by the geographic distribution of these accred-
ited cancer centres because out of the 40 OECI accred-
ited centres, there is only one OECI accredited CCC
and five accredited CCs in the Central-Eastern EU
region (Fig. 2). The ERN PaedCan unites 57 Full
Members from 18 countries and a further 12 Affiliated
Partners from eight countries (Fig. 4).
7. Relationship between the cancer
mission and Europe’s Beating Cancer
Plan
The decision to support European cancer activities
with both a European Beating Cancer Plan (https://
ec.europa.eu/health/non_communicable_diseases/cance
r_en) and a cancer mission is timely and strategically
relevant. There are apparent inequalities both within
and among EU countries concerning cancer treatment,
or care, and cancer prevention. For example, access to
early detection programmes, advanced diagnostic
methods, immunotherapy, precision medicine, state-of-
the-art surgery, radiation therapy, functional/molecu-
lar imaging or rehabilitation is highly variable. The
EU project European Network for Cancer Research in
Children and Adolescents (https://siope.eu/activities/
eu-projects/encca/) also demonstrated significant
inequalities in paediatric oncology between EU coun-
tries. The Europe’s Beating Cancer Plan will be valu-
able to coordinate national cancer plans to make
better use of evidence-based cancer treatment/care and
prevention. The latter will mitigate inequalities by sup-
porting national programmes for equal access to can-
cer patients and survivors.
8. Concluding remarks
A comprehensive translational cancer research
approach that is focused on personalized/precision
medicine and covers the entire cancer research-preven-
tion-care continuum has the potential to achieve in
2030 the goal of a 10-year cancer-specific survival for
75% of the patients diagnosed in EU Member states
with a well-developed healthcare system. Expected
effects of primary prevention on incidence and mortal-
ity is a more long-term goal to be assessed by age-s-
tandardized mortality monitoring. Concerted actions
across this continuum that spans from basic and pre-
clinical research through clinical and prevention
research to outcomes research, as well as the establish-
ment of high-quality networked infrastructures will
pave the way not only to clinical innovation, but also
to the mitigation of economic and social inequalities
across European countries.
Here, we propose the establishment of three types of
infrastructures focusing on translational research, clini-
cal and prevention trials, and outcomes research.
These infrastructures, embodied in CCCs or CCC-like
entities, will provide researchers with access to a criti-
cal mass of patients, biological materials and techno-
logical resources, bridging research and health care.
The latter will warrant that future scientific and social
innovations benefit cancer patients across the health-
care systems in Europe.
We prioritized 13 research areas to achieve a bal-
anced research portfolio, namely: basic and preclinical
research; primary prevention; early detection for pre-
vention and treatment; development of new therapies;
psychosocial oncology, rehabilitation, and survivorship
research; palliative oncology; paediatric oncology; geri-
atric oncology; outcomes research; health economics;
big data and computational science. We have worked
together to provide recommendations for each of the
above areas; these recommendations will be, in our
view, important for achieving key targets. We also
offer suggestions as to how to strengthen patients’
empowerment, improve specialist education, and
decrease present inequalities in cancer research within
the EU.
Box 14
Recommendations for addressing inequalities in cancer
research.
 Strengthen Central-Eastern European cancer centres
with effective utilization of OECI’s Accreditation and
Designation programme, and EACS’s Designation of
Excellence (DoE) programme via collaboration with
the CEEAO.
 Extend and strengthen the Paediatric Cancer Expert
Reference Network to be accessible to children with
cancer throughout Europe. Promote concentration of
paediatric cancer research and care where feasible.
 Support cancer research activities that address region-
specific issues in cancer care, prevention, research and
training within Europe.
 Open dedicated calls for proposals in the Central-
Eastern EU region to decrease inequalities in basic,
clinical and translational cancer research.
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Meeting key objectives will require further harmo-
nization of EU and national priorities and policies,
improved research coordination at the national, regio-
nal and EU level, as well as more efficient and flexible
funding mechanisms. It is also crucial to ensure the sus-
tainability of trans-border infrastructures and net-
works, for example through long-term support directly
by the EU, or other schemes to which Member State
countries commit. It will require political will and
perseverance to bridge the gaps in science, society and
policy that affect cancer treatment and care [91].
Science policy is often developed in isolation [91];
therefore, it will be crucial to engage policymakers and
to ensure that all the relevant stakeholders along the
entire research–care–prevention continuum speak with
a single voice to provide evidence-based advice to
inform policy [25,91]. In addition, careful forward
planning will be pivotal to ensure a successful outcome.
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A concerted cancer science policy in Europe is an
unmet need [91]. Appointing a policy board with mul-
tiple competencies will be necessary to identify the best
strategies to implement the comprehensive range of
activities necessary to accomplish the mission goals.
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